Financial Statements

Alnylam Pharmaceuticals, Inc. (ALNY)

$127.77

+2.17 (+1.73%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) -4,585-3,727-2,841-2,148-
Net Income -853-858-886-761-491
Stock Dividends ---68-1,657
Dividend Paid -----
Retained Earnings -5,438-4,585-3,727-2,841-2,148

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 707425321182-
Annual Depreciation 14352245266286
Capital Expenditure 14-70-140-127-104
Net PPE 734707425321182

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -----
New Purchases -903-1,104-2,076-2,026-1,656
Intangible and Goodwill -----

Alnylam Pharmaceuticals, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Alnylam Pharmaceuticals, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.